Effects of dexmedetomidine combined with abdominal wall block on postoperative recovery quality and inflammatory response in patients undergoing laparoscopic colorectal surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039295

Enrollment

Unknown

Registered

2020-10-22

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Group 1:0.25% ropivacaine was given 60mL bilateral RSB(20mL)+TAPB(40mL), and normal saline was injected with 10mL intravenous pump for 1h

Group 2:0.8ug/kg dexmedetomidine was added with 0.25% ropivacaine for 60mL of bilateral RSB+TAPB, and normal saline was injected with 10mL intravenous pump for 1h

Group 3:In the same control group, dexmedetomidine was diluted with 0.8ug/kg to 10mL and intravenously pumped for 1h

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who plan to undergo laparoscopic radical resection of colorectal cancer; 2. ASA I - II patients; 3. Patients aged 20-70 years; 4. BMI20-30kg/m2.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to the drugs involved in the research program; 2. Patients with systemic or puncture site infection; 3. Patients with bradycardia or atrioventricular block; 4. Patients with abnormal liver and kidney function before operation; 5. Patients who had received chemoradiotherapy or immunotherapy before operation; 6. Patients with hypertension, diabetes, mental illness or other tumors.

Design outcomes

Primary

Measure	Time frame
QoR-40;NLR;	—

Countries

China

Contacts

Public ContactHongying Tan

Cancer Center of Sun Yat-Sen University

tanhongy@sysucc.org.cn+86 13556063870

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026